<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02220270</url>
  </required_header>
  <id_info>
    <org_study_id>COM-01 V1.0 17 June 2014</org_study_id>
    <nct_id>NCT02220270</nct_id>
  </id_info>
  <brief_title>Hyperion™ International Registry Trial</brief_title>
  <acronym>COM-01</acronym>
  <official_title>A Prospective, Multi-center Study to Evaluate the Safety and Performance of the Hyperion™ ASD and PDA Closure Systems.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Cardiovascular Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Comed B.V.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>European Cardiovascular Research Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety, performance and efficacy of the
      Hyperion™ Occluder Systems during treatment of ASD and PDA patients.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2015</start_date>
  <completion_date type="Anticipated">August 2017</completion_date>
  <primary_completion_date type="Anticipated">November 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Success of implantation</measure>
    <time_frame>30 days</time_frame>
    <description>Success of implantation without death, stroke, any device embolization, puncture site bleeding requiring surgical repair or blood transfusion and without any other device or procedure related MAE at 30 days</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Device success</measure>
    <time_frame>6 months</time_frame>
    <description>Device success defined as ASD or PDA closure at 6 months post procedure by a Transthoracic echocardiography (TTE) or a Transesophageal echocardiography (TEE).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Major Adverse Events</measure>
    <time_frame>30 days, 6 and 12 months</time_frame>
    <description>Major Adverse Events at 6 and 12 months defined as composite rate of all death, stroke, any device embolization, puncture site bleeding requiring surgical repair or blood transfusion at discharge and any other device or procedure related MAE.
Components of Major Adverse Events at discharge, 30 days, 6, and 12 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedure success</measure>
    <time_frame>6 months</time_frame>
    <description>Procedure success defined as successful deployment of the Hyperion™ Closure System in the patient's ASD and PDA, closure (residual shunt &lt; 3mm) at 6 months.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Atrial Septal Defects</condition>
  <condition>Patent Ductus Arteriosus</condition>
  <arm_group>
    <arm_group_label>patient with PDA or ASD</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ASD and PDA closure</intervention_name>
    <arm_group_label>patient with PDA or ASD</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patient who comes to hospital for ASD or PDA closure
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient has ASD or PDA documented by a Transoesophagial echocardiography (TEE) or a
             Transthoracic echocardiography (TTE) and indication for closure that is amenable to
             treatment with the Hyperion™ ASD or PDA occluder

          -  For PDA: Patient age ≥ 1 year old

          -  For ASD: Patient weighting ≥15 kg of any age

          -  Patient is willing and able to comply with specified follow-up evaluations

          -  Patient or legally authorized representative has been informed of the nature of the
             study, agrees to its provisions and has been provided written Notice of Informed
             Consent, approved by the appropriate Ethics Committee (EC)

        Exclusion Criteria:

          -  Pregnant or nursing subjects and those who plan pregnancy in the period up to 1 year
             following index procedure. Female subjects of child-bearing potential must have a
             negative pregnancy test done within 7 days prior to the index procedure per site
             standard test

          -  Patient has other medical illness (e.g., cancer, known malignancy, congestive heart
             failure, organ transplant recipient or candidate) or known history of substance abuse
             (alcohol, cocaine, heroin etc.) that may cause non-compliance with the protocol,
             confound the data interpretation or is associated with a limited life expectancy
             (i.e., less than 1 year)

          -  Patient has a known hypersensitivity or contraindication to aspirin, heparin, and/or
             contrast sensitivity that cannot be adequately pre-medicated

          -  Currently participating in another clinical study

          -  Active endocarditis, active bacterial infection, or other infection producing
             bacteremia or sepsis

          -  Congenital or structural heart disease other than ASD or PDA

          -  Thrombus at the intended site of implant or documented venous thrombosis in venous
             access

          -  Severe pulmonary hypertension

          -  Vascular anatomy unable to accommodate the appropriate-sized sheath for device
             introduction

          -  ASD or PDA anatomy non suitable for the Hyperion™ closure device

          -  Confinement to bed (increased risk for clot formation)

          -  Prior cardiac implantation of cardiac devices for ASD or PDA closure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jean-François Piechaud, MD</last_name>
    <phone>0 60 13 46 20</phone>
    <phone_ext>33</phone_ext>
    <email>jfpiechaud@angio-icps.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Frantz-Fanon</name>
      <address>
        <city>Blida</city>
        <country>Algeria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohamed Chettibi, MD</last_name>
      <email>med.chettibi@yahoo.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Radjah Clinic</name>
      <address>
        <city>Setif</city>
        <country>Algeria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean-François Peichaud</last_name>
    </contact>
    <investigator>
      <last_name>Jean-François Piechaud</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Médico-chirurgical infantile Bou Ismail</name>
      <address>
        <city>Tipaza</city>
        <country>Algeria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohamed Touati, MD</last_name>
      <email>mohamedtouati@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Anzhen Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hong Gu, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai Children's Medical Center</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fen Li, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital cardiologique Haut-Leveque (CHU Bordeaux)</name>
      <address>
        <city>Bordeaux</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean-Benoit Thambo</last_name>
      <email>jean-benoit.thambo@chu-bordeaux.fr</email>
    </contact>
    <investigator>
      <last_name>Jean-Benoit Thambo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Privé Jacques Cartier</name>
      <address>
        <city>Massy</city>
        <zip>91300</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-François Piechaud, MD</last_name>
      <email>Piechjfpiechaud@angio-icps.com</email>
    </contact>
    <investigator>
      <last_name>Jean-François Piechaud, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Necker Enfants Malades</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Younes Boudjemline, MD</last_name>
      <email>yboudjemline@yahoo.fr</email>
    </contact>
    <investigator>
      <last_name>Younes Boudjemline, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>American Memorial Hospital</name>
      <address>
        <city>Reims</city>
        <zip>51100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pierre Mauran</last_name>
      <email>pmauran@chu-reims.fr</email>
    </contact>
    <investigator>
      <last_name>Pierre Mauran, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CardioVascular Center Frankfurt</name>
      <address>
        <city>Frankfurt</city>
        <zip>60389</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Horst SIEVERT</last_name>
      <email>horstsievertmd@aol.com</email>
    </contact>
    <investigator>
      <last_name>Horst Sievert, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Algeria</country>
    <country>China</country>
    <country>France</country>
    <country>Germany</country>
  </location_countries>
  <removed_countries>
    <country>United Kingdom</country>
  </removed_countries>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 14, 2014</study_first_submitted>
  <study_first_submitted_qc>August 18, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 19, 2014</study_first_posted>
  <last_update_submitted>August 17, 2015</last_update_submitted>
  <last_update_submitted_qc>August 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 19, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ductus Arteriosus, Patent</mesh_term>
    <mesh_term>Heart Septal Defects</mesh_term>
    <mesh_term>Heart Septal Defects, Atrial</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

